Amrut Ambardekar
Concepts (444)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 39 | 2026 | 570 | 7.870 |
Why?
| | Heart Failure | 55 | 2026 | 2323 | 5.970 |
Why?
| | Heart Transplantation | 25 | 2025 | 679 | 4.600 |
Why?
| | Cardiomyopathies | 17 | 2026 | 339 | 3.560 |
Why?
| | Amyloid Neuropathies, Familial | 10 | 2026 | 26 | 2.970 |
Why?
| | Prealbumin | 9 | 2026 | 37 | 1.710 |
Why?
| | Amyloidosis | 4 | 2023 | 43 | 1.670 |
Why?
| | Heart Ventricles | 9 | 2020 | 762 | 1.480 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2020 | 357 | 1.040 |
Why?
| | Cardiology | 3 | 2026 | 363 | 1.040 |
Why?
| | Myocardium | 11 | 2026 | 948 | 1.020 |
Why?
| | Myocytes, Cardiac | 14 | 2026 | 542 | 0.990 |
Why?
| | Ventricular Dysfunction, Left | 8 | 2023 | 391 | 0.980 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2024 | 144 | 0.900 |
Why?
| | Gene Editing | 1 | 2026 | 89 | 0.860 |
Why?
| | Humans | 114 | 2026 | 145625 | 0.840 |
Why?
| | Genetic Therapy | 1 | 2026 | 303 | 0.800 |
Why?
| | Arrhythmias, Cardiac | 6 | 2022 | 358 | 0.790 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 248 | 0.770 |
Why?
| | Graft Rejection | 4 | 2025 | 504 | 0.740 |
Why?
| | Rejuvenation | 1 | 2022 | 18 | 0.730 |
Why?
| | Defibrillators, Implantable | 4 | 2020 | 393 | 0.720 |
Why?
| | Assisted Circulation | 2 | 2021 | 26 | 0.710 |
Why?
| | Stroke Volume | 10 | 2026 | 651 | 0.710 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 43 | 0.700 |
Why?
| | Transplant Recipients | 4 | 2021 | 168 | 0.690 |
Why?
| | Fibrosis | 5 | 2022 | 568 | 0.690 |
Why?
| | Echocardiography | 7 | 2017 | 645 | 0.680 |
Why?
| | Hemodynamics | 7 | 2023 | 1114 | 0.660 |
Why?
| | Vascular Stiffness | 2 | 2017 | 488 | 0.660 |
Why?
| | Calcineurin Inhibitors | 1 | 2021 | 67 | 0.650 |
Why?
| | Giant Cells | 1 | 2020 | 21 | 0.650 |
Why?
| | Middle Aged | 42 | 2026 | 36359 | 0.640 |
Why?
| | Arteries | 1 | 2022 | 260 | 0.640 |
Why?
| | Immunosuppressive Agents | 5 | 2021 | 824 | 0.630 |
Why?
| | Aortic Diseases | 1 | 2021 | 124 | 0.620 |
Why?
| | Heart Neoplasms | 1 | 2020 | 56 | 0.620 |
Why?
| | Ventricular Function, Left | 7 | 2023 | 541 | 0.610 |
Why?
| | Sarcoma, Kaposi | 1 | 2020 | 82 | 0.610 |
Why?
| | Myocarditis | 1 | 2020 | 102 | 0.590 |
Why?
| | Male | 58 | 2026 | 73014 | 0.590 |
Why?
| | Coronary Vessels | 2 | 2018 | 245 | 0.590 |
Why?
| | Ventricular Remodeling | 5 | 2026 | 283 | 0.580 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 300 | 0.570 |
Why?
| | Myocardial Contraction | 4 | 2020 | 292 | 0.550 |
Why?
| | Brugada Syndrome | 2 | 2009 | 14 | 0.550 |
Why?
| | Aged | 30 | 2026 | 26251 | 0.540 |
Why?
| | Heart | 6 | 2023 | 624 | 0.540 |
Why?
| | Female | 56 | 2026 | 79080 | 0.530 |
Why?
| | Extracellular Matrix | 1 | 2021 | 564 | 0.500 |
Why?
| | Bariatric Surgery | 1 | 2021 | 248 | 0.500 |
Why?
| | Treatment Outcome | 17 | 2026 | 11744 | 0.500 |
Why?
| | Cardiovascular Diseases | 2 | 2026 | 2218 | 0.490 |
Why?
| | Myocardial Ischemia | 4 | 2019 | 286 | 0.480 |
Why?
| | Cryosurgery | 1 | 2016 | 46 | 0.460 |
Why?
| | Heart Rate | 2 | 2021 | 844 | 0.440 |
Why?
| | Thrombosis | 2 | 2016 | 397 | 0.430 |
Why?
| | Benzoic Acid | 4 | 2026 | 9 | 0.410 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 179 | 0.410 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 271 | 0.410 |
Why?
| | Blood Pressure | 5 | 2022 | 1761 | 0.410 |
Why?
| | Marijuana Abuse | 1 | 2016 | 215 | 0.390 |
Why?
| | Electrocardiography | 4 | 2020 | 666 | 0.390 |
Why?
| | Aorta, Thoracic | 1 | 2015 | 284 | 0.370 |
Why?
| | Myofibrils | 3 | 2022 | 55 | 0.360 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 595 | 0.360 |
Why?
| | Patient-Centered Care | 2 | 2021 | 551 | 0.360 |
Why?
| | Alternative Splicing | 2 | 2026 | 249 | 0.350 |
Why?
| | Recovery of Function | 3 | 2026 | 721 | 0.350 |
Why?
| | Adult | 23 | 2026 | 40821 | 0.330 |
Why?
| | Guideline Adherence | 3 | 2011 | 585 | 0.330 |
Why?
| | Patient Compliance | 2 | 2017 | 587 | 0.320 |
Why?
| | Cardiac Tamponade | 1 | 2010 | 15 | 0.310 |
Why?
| | Pyrazoles | 4 | 2026 | 516 | 0.310 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 173 | 0.300 |
Why?
| | Calcium | 4 | 2023 | 1181 | 0.300 |
Why?
| | Baroreflex | 2 | 2021 | 55 | 0.300 |
Why?
| | Electric Stimulation Therapy | 1 | 2010 | 63 | 0.300 |
Why?
| | Risk Assessment | 6 | 2021 | 3678 | 0.300 |
Why?
| | Sarcomeres | 3 | 2022 | 100 | 0.300 |
Why?
| | Hospitals, Rural | 1 | 2009 | 49 | 0.290 |
Why?
| | Cardiac Output | 3 | 2023 | 176 | 0.290 |
Why?
| | Safety | 1 | 2011 | 346 | 0.290 |
Why?
| | Double-Blind Method | 4 | 2026 | 2064 | 0.290 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2009 | 83 | 0.290 |
Why?
| | Hospitals, Urban | 1 | 2009 | 140 | 0.290 |
Why?
| | Automobile Driving | 1 | 2011 | 156 | 0.290 |
Why?
| | Cannabis | 1 | 2016 | 519 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2623 | 0.280 |
Why?
| | Pulsatile Flow | 2 | 2018 | 62 | 0.280 |
Why?
| | Mastitis | 1 | 2007 | 6 | 0.270 |
Why?
| | Counseling | 1 | 2011 | 403 | 0.260 |
Why?
| | Vascular Remodeling | 2 | 2021 | 208 | 0.260 |
Why?
| | Registries | 6 | 2021 | 2382 | 0.260 |
Why?
| | Antiviral Agents | 2 | 2025 | 774 | 0.260 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1500 | 0.260 |
Why?
| | Puerperal Disorders | 1 | 2007 | 35 | 0.260 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2023 | 69 | 0.260 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 339 | 0.260 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5397 | 0.260 |
Why?
| | Coronary Disease | 1 | 2009 | 380 | 0.250 |
Why?
| | Cytomegalovirus | 2 | 2025 | 169 | 0.250 |
Why?
| | Environment | 1 | 2009 | 295 | 0.250 |
Why?
| | Length of Stay | 2 | 2009 | 1342 | 0.240 |
Why?
| | RNAi Therapeutics | 1 | 2026 | 7 | 0.240 |
Why?
| | Retrospective Studies | 14 | 2025 | 17291 | 0.240 |
Why?
| | Prospective Studies | 10 | 2021 | 8087 | 0.240 |
Why?
| | Oligonucleotides, Antisense | 1 | 2026 | 122 | 0.230 |
Why?
| | Diastole | 2 | 2018 | 147 | 0.230 |
Why?
| | Oligonucleotides | 1 | 2026 | 154 | 0.230 |
Why?
| | Troponin I | 2 | 2019 | 74 | 0.220 |
Why?
| | Inpatients | 1 | 2009 | 538 | 0.220 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2025 | 34 | 0.220 |
Why?
| | Heart Failure, Systolic | 2 | 2024 | 26 | 0.210 |
Why?
| | HIV Infections | 1 | 2020 | 3210 | 0.210 |
Why?
| | Quality of Health Care | 1 | 2009 | 692 | 0.210 |
Why?
| | Methyltransferases | 1 | 2025 | 73 | 0.210 |
Why?
| | Biomarkers | 4 | 2026 | 4329 | 0.210 |
Why?
| | United States | 10 | 2026 | 16041 | 0.200 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 203 | 0.200 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 8 | 0.190 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2026 | 199 | 0.190 |
Why?
| | Prognosis | 6 | 2025 | 4331 | 0.190 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 32 | 0.190 |
Why?
| | Quality of Life | 6 | 2024 | 3187 | 0.190 |
Why?
| | MicroRNAs | 2 | 2022 | 695 | 0.190 |
Why?
| | Physical Conditioning, Animal | 1 | 2025 | 242 | 0.190 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2228 | 0.190 |
Why?
| | Heart Injuries | 1 | 2023 | 41 | 0.190 |
Why?
| | Perioperative Care | 2 | 2017 | 229 | 0.180 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2022 | 46 | 0.180 |
Why?
| | Preoperative Care | 2 | 2017 | 375 | 0.180 |
Why?
| | Practice Guidelines as Topic | 3 | 2025 | 1581 | 0.180 |
Why?
| | Metalloproteases | 1 | 2022 | 42 | 0.180 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 115 | 0.180 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 441 | 0.180 |
Why?
| | Cadherin Related Proteins | 1 | 2022 | 12 | 0.180 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.180 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 16 | 0.180 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 13 | 0.180 |
Why?
| | Patient Transfer | 2 | 2019 | 223 | 0.170 |
Why?
| | Succinic Acid | 2 | 2019 | 46 | 0.170 |
Why?
| | Cohort Studies | 6 | 2023 | 6045 | 0.170 |
Why?
| | Triage | 1 | 2024 | 243 | 0.170 |
Why?
| | Societies, Medical | 1 | 2026 | 901 | 0.170 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 120 | 0.170 |
Why?
| | Recurrence | 2 | 2025 | 1125 | 0.170 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 20 | 0.170 |
Why?
| | Leukopenia | 1 | 2021 | 33 | 0.170 |
Why?
| | Hospitalization | 4 | 2024 | 2468 | 0.170 |
Why?
| | Cardiovascular System | 1 | 2023 | 137 | 0.170 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 219 | 0.170 |
Why?
| | Pressoreceptors | 1 | 2021 | 19 | 0.160 |
Why?
| | Mice | 13 | 2025 | 18266 | 0.160 |
Why?
| | Carrier Proteins | 2 | 2022 | 728 | 0.160 |
Why?
| | Hypertension | 2 | 2020 | 1270 | 0.160 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 117 | 0.160 |
Why?
| | Muscle Proteins | 1 | 2022 | 242 | 0.160 |
Why?
| | Case-Control Studies | 4 | 2022 | 3633 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 705 | 0.160 |
Why?
| | Cell Adhesion | 2 | 2018 | 447 | 0.160 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1709 | 0.150 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1212 | 0.150 |
Why?
| | Transcriptome | 3 | 2025 | 1066 | 0.150 |
Why?
| | Animals | 17 | 2026 | 38030 | 0.150 |
Why?
| | HIV | 1 | 2020 | 249 | 0.140 |
Why?
| | Disease Progression | 2 | 2018 | 2857 | 0.140 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2020 | 140 | 0.140 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2910 | 0.140 |
Why?
| | Aortic Valve | 1 | 2022 | 360 | 0.140 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 299 | 0.140 |
Why?
| | Terminology as Topic | 1 | 2020 | 253 | 0.140 |
Why?
| | Exercise Test | 4 | 2023 | 634 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 371 | 0.140 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 196 | 0.130 |
Why?
| | Longitudinal Studies | 3 | 2016 | 3005 | 0.130 |
Why?
| | Rats | 6 | 2026 | 5574 | 0.130 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 269 | 0.130 |
Why?
| | Filamins | 1 | 2018 | 28 | 0.130 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 186 | 0.130 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 364 | 0.130 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 263 | 0.130 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 16 | 0.130 |
Why?
| | Mutation | 2 | 2018 | 4082 | 0.120 |
Why?
| | Immunity, Cellular | 1 | 2018 | 277 | 0.120 |
Why?
| | Caliciviridae Infections | 1 | 2016 | 18 | 0.120 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 166 | 0.120 |
Why?
| | Down-Regulation | 2 | 2016 | 612 | 0.120 |
Why?
| | ErbB Receptors | 1 | 2020 | 636 | 0.120 |
Why?
| | Pilot Projects | 3 | 2019 | 1878 | 0.120 |
Why?
| | Histone Deacetylases | 1 | 2018 | 208 | 0.120 |
Why?
| | Self Care | 1 | 2019 | 396 | 0.120 |
Why?
| | Brain | 2 | 2018 | 2981 | 0.120 |
Why?
| | Time Factors | 5 | 2024 | 7079 | 0.120 |
Why?
| | Polypharmacy | 1 | 2017 | 94 | 0.120 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 293 | 0.120 |
Why?
| | Anesthetics | 1 | 2017 | 100 | 0.120 |
Why?
| | Eligibility Determination | 1 | 2016 | 72 | 0.120 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 68 | 0.110 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2018 | 271 | 0.110 |
Why?
| | Benzoxazoles | 2 | 2026 | 20 | 0.110 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2015 | 24 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2021 | 1979 | 0.110 |
Why?
| | Drug Interactions | 1 | 2017 | 403 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 530 | 0.110 |
Why?
| | Prosthesis Design | 3 | 2014 | 357 | 0.110 |
Why?
| | Transition to Adult Care | 1 | 2017 | 108 | 0.110 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 93 | 0.110 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 427 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1062 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1790 | 0.110 |
Why?
| | Phosphorylation | 3 | 2019 | 1717 | 0.110 |
Why?
| | Consensus | 3 | 2023 | 465 | 0.110 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2026 | 110 | 0.110 |
Why?
| | Tacrolimus | 1 | 2016 | 192 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 342 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2026 | 8351 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2016 | 110 | 0.110 |
Why?
| | Viscosity | 1 | 2015 | 91 | 0.110 |
Why?
| | Postoperative Care | 1 | 2017 | 292 | 0.110 |
Why?
| | Hospital Mortality | 2 | 2009 | 1037 | 0.110 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 53 | 0.110 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1318 | 0.100 |
Why?
| | Elastic Modulus | 1 | 2015 | 121 | 0.100 |
Why?
| | Cardiovascular Agents | 2 | 2020 | 165 | 0.100 |
Why?
| | Health Status | 1 | 2019 | 822 | 0.100 |
Why?
| | Attitude to Health | 1 | 2017 | 419 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 751 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2018 | 410 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2020 | 699 | 0.100 |
Why?
| | Risk Factors | 5 | 2025 | 10840 | 0.100 |
Why?
| | Systole | 1 | 2014 | 179 | 0.100 |
Why?
| | Hip Prosthesis | 1 | 2014 | 42 | 0.100 |
Why?
| | Shock, Cardiogenic | 1 | 2014 | 65 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1411 | 0.100 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1429 | 0.100 |
Why?
| | Vaccination | 1 | 2022 | 1444 | 0.100 |
Why?
| | Incidence | 3 | 2019 | 2910 | 0.100 |
Why?
| | Patient Selection | 2 | 2017 | 720 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2014 | 125 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 2016 | 248 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2025 | 2962 | 0.090 |
Why?
| | Blood Coagulation | 1 | 2014 | 267 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2017 | 627 | 0.090 |
Why?
| | Patient Education as Topic | 1 | 2017 | 769 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1325 | 0.090 |
Why?
| | Graft Survival | 2 | 2025 | 508 | 0.090 |
Why?
| | Ventricular Premature Complexes | 1 | 2012 | 37 | 0.090 |
Why?
| | Mice, Knockout | 3 | 2025 | 3121 | 0.090 |
Why?
| | Young Adult | 6 | 2019 | 14240 | 0.080 |
Why?
| | Biopsy | 1 | 2015 | 1073 | 0.080 |
Why?
| | Natriuretic Peptides | 1 | 2011 | 9 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2016 | 739 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3396 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 3 | 2026 | 2533 | 0.080 |
Why?
| | Neurotransmitter Agents | 1 | 2011 | 84 | 0.080 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 1212 | 0.080 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2011 | 58 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2010 | 959 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2020 | 2591 | 0.080 |
Why?
| | Connectin | 2 | 2022 | 43 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2022 | 176 | 0.080 |
Why?
| | Endpoint Determination | 2 | 2020 | 84 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 987 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1992 | 0.080 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 203 | 0.080 |
Why?
| | Pericardial Effusion | 1 | 2010 | 22 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 228 | 0.080 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 156 | 0.080 |
Why?
| | Heart Septum | 1 | 2009 | 27 | 0.080 |
Why?
| | Stroke | 1 | 2019 | 1283 | 0.070 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 252 | 0.070 |
Why?
| | DNA | 1 | 2016 | 1418 | 0.070 |
Why?
| | Comorbidity | 2 | 2020 | 1652 | 0.070 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 85 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2022 | 4112 | 0.070 |
Why?
| | Anticoagulants | 1 | 2014 | 743 | 0.070 |
Why?
| | Disease Management | 2 | 2025 | 649 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1403 | 0.070 |
Why?
| | Exercise | 1 | 2020 | 2206 | 0.070 |
Why?
| | Ultrasonography | 1 | 2012 | 788 | 0.070 |
Why?
| | Europe | 2 | 2020 | 420 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2022 | 4565 | 0.070 |
Why?
| | Transcription Factors | 1 | 2016 | 1728 | 0.070 |
Why?
| | Coronary Circulation | 1 | 2008 | 134 | 0.070 |
Why?
| | Syndrome | 1 | 2008 | 377 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 6021 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 727 | 0.060 |
Why?
| | Blood Flow Velocity | 1 | 2008 | 419 | 0.060 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 569 | 0.060 |
Why?
| | Body Temperature | 1 | 2007 | 227 | 0.060 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 297 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2023 | 942 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2455 | 0.060 |
Why?
| | Survivors | 1 | 2009 | 521 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 427 | 0.050 |
Why?
| | Clinical Protocols | 2 | 2017 | 279 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2009 | 566 | 0.050 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2025 | 198 | 0.050 |
Why?
| | Genotype | 2 | 2020 | 1866 | 0.050 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2023 | 37 | 0.050 |
Why?
| | Troponin | 1 | 2023 | 50 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2079 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 867 | 0.050 |
Why?
| | Travel | 1 | 2023 | 133 | 0.050 |
Why?
| | Histone Deacetylase 6 | 1 | 2022 | 17 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 133 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 93 | 0.040 |
Why?
| | Catecholamines | 1 | 2022 | 88 | 0.040 |
Why?
| | Up-Regulation | 1 | 2025 | 840 | 0.040 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2002 | 37 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2026 | 693 | 0.040 |
Why?
| | Thiophenes | 1 | 2022 | 117 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1370 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5875 | 0.040 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 66 | 0.040 |
Why?
| | Calcium Channels | 1 | 2022 | 157 | 0.040 |
Why?
| | Death, Sudden, Cardiac | 1 | 2023 | 242 | 0.040 |
Why?
| | Signal Transduction | 3 | 2021 | 5234 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 333 | 0.040 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 8 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2002 | 151 | 0.040 |
Why?
| | Phenylephrine | 1 | 2021 | 74 | 0.040 |
Why?
| | Anaerobic Threshold | 1 | 2021 | 29 | 0.040 |
Why?
| | Adolescent | 4 | 2019 | 22451 | 0.040 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2020 | 16 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2022 | 388 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 63 | 0.040 |
Why?
| | Chronic Disease | 2 | 2017 | 1824 | 0.040 |
Why?
| | Culture Media | 1 | 2021 | 160 | 0.040 |
Why?
| | Prevalence | 2 | 2018 | 2852 | 0.040 |
Why?
| | Cardiomegaly | 1 | 2022 | 175 | 0.040 |
Why?
| | Heart Valve Diseases | 1 | 2002 | 150 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2023 | 746 | 0.040 |
Why?
| | Survival Rate | 1 | 2025 | 2078 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2021 | 140 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2020 | 59 | 0.040 |
Why?
| | Norepinephrine | 1 | 2021 | 201 | 0.040 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2020 | 63 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 494 | 0.040 |
Why?
| | Acylation | 1 | 2019 | 30 | 0.040 |
Why?
| | Electric Countershock | 1 | 2020 | 126 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 69 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 610 | 0.040 |
Why?
| | Program Evaluation | 2 | 2017 | 945 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2023 | 353 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2020 | 104 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 456 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 200 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 192 | 0.040 |
Why?
| | Seizures | 1 | 2023 | 489 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 241 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 325 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2020 | 339 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2020 | 494 | 0.030 |
Why?
| | Pyridines | 1 | 2022 | 606 | 0.030 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.030 |
Why?
| | Internship and Residency | 1 | 2009 | 1269 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2021 | 719 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 95 | 0.030 |
Why?
| | Fatty Acids | 1 | 2021 | 460 | 0.030 |
Why?
| | Hyperplasia | 1 | 2018 | 164 | 0.030 |
Why?
| | Myosins | 1 | 2018 | 131 | 0.030 |
Why?
| | Lysine | 1 | 2019 | 302 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 460 | 0.030 |
Why?
| | Autoradiography | 1 | 2017 | 64 | 0.030 |
Why?
| | Fluorine Radioisotopes | 1 | 2017 | 14 | 0.030 |
Why?
| | Zebrafish | 1 | 2022 | 533 | 0.030 |
Why?
| | Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
| | Fibroblasts | 1 | 2022 | 1033 | 0.030 |
Why?
| | Antidiarrheals | 1 | 2016 | 12 | 0.030 |
Why?
| | Alleles | 1 | 2020 | 900 | 0.030 |
Why?
| | Loperamide | 1 | 2016 | 12 | 0.030 |
Why?
| | Atropine | 1 | 2016 | 37 | 0.030 |
Why?
| | Papio | 1 | 2017 | 70 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 409 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2017 | 150 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 6050 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2020 | 438 | 0.030 |
Why?
| | Tissue Donors | 1 | 2019 | 398 | 0.030 |
Why?
| | Transcription Initiation Site | 1 | 2016 | 43 | 0.030 |
Why?
| | Transcription Elongation, Genetic | 1 | 2016 | 24 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 218 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 502 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 62 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2017 | 210 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 899 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 152 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 771 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 262 | 0.030 |
Why?
| | Actins | 1 | 2018 | 422 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2020 | 514 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 399 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2809 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2018 | 449 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 538 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1372 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2097 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 26 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2131 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 878 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 1125 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3917 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 207 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 771 | 0.030 |
Why?
| | Cobalt | 1 | 2014 | 50 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1030 | 0.020 |
Why?
| | Action Potentials | 1 | 2017 | 498 | 0.020 |
Why?
| | Models, Biological | 1 | 2021 | 1758 | 0.020 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 6 | 0.020 |
Why?
| | Reoperation | 1 | 2016 | 633 | 0.020 |
Why?
| | Warfarin | 1 | 2014 | 179 | 0.020 |
Why?
| | Self Report | 1 | 2017 | 869 | 0.020 |
Why?
| | Heparin | 1 | 2014 | 246 | 0.020 |
Why?
| | RNA Polymerase II | 1 | 2016 | 347 | 0.020 |
Why?
| | Creatine | 1 | 2013 | 63 | 0.020 |
Why?
| | Mass Screening | 1 | 2021 | 1300 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 535 | 0.020 |
Why?
| | Proteomics | 1 | 2019 | 1202 | 0.020 |
Why?
| | Glutamine | 1 | 2013 | 110 | 0.020 |
Why?
| | Child, Preschool | 2 | 2019 | 11888 | 0.020 |
Why?
| | Antibodies | 1 | 2014 | 395 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 629 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1843 | 0.020 |
Why?
| | Chromatin | 1 | 2016 | 557 | 0.020 |
Why?
| | Alanine | 1 | 2013 | 171 | 0.020 |
Why?
| | Dyspnea | 1 | 2014 | 251 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2020 | 2783 | 0.020 |
Why?
| | Lactic Acid | 1 | 2013 | 295 | 0.020 |
Why?
| | Fatigue | 1 | 2014 | 362 | 0.020 |
Why?
| | Depression | 1 | 2021 | 1566 | 0.020 |
Why?
| | Phenotype | 1 | 2020 | 3186 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 952 | 0.020 |
Why?
| | Patient Discharge | 1 | 2016 | 991 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2101 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3321 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2012 | 355 | 0.020 |
Why?
| | Glucose | 1 | 2013 | 1051 | 0.020 |
Why?
| | Child | 2 | 2019 | 22638 | 0.020 |
Why?
| | Focus Groups | 1 | 2009 | 587 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2009 | 743 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10093 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 355 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1261 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|